

## Title Page Template

*Please fill out each of the below sections. If any are not applicable, please enter N/A*

- **Article title:** Fluorescein-entrapped magnetosomes for magnetically assisted photodynamic therapy
- **Short running title:** FL-Magnetosomes for enhanced PDT.  
<50 characters including spaces.
- **Author names:** Parul<sup>1</sup>, T. Sen<sup>2</sup> and I. Roy<sup>1†</sup>
  - **Guidance on author sequence:** Author sequence is at the authors' discretion; however, Future Medicine journals suggest following the recommendations in GPP3 Appendix Table 2 (<http://www.ismpp.org/gpp3>), whereby authors are listed either in order of the level of their contribution, or alphabetically. The corresponding author should always be indicated.
- **Author affiliations:** <sup>1</sup>Department of Chemistry, University of Delhi, Delhi 110007, India  
<sup>2</sup>University of Central Lancashire, Preston, United Kingdom
- **ORCID iD:** During the submission process, please consider adding an ORCID iD to your account on the manuscript submission site. An ORCID iD is a unique and persistent digital identifier that ensures your work is correctly associated with you, regardless of whether your name is similar to (or the same as) another individual, or if your name changes. When you login to your account on ScholarOne, you can either associate your existing ORCID iD with your account, or register with ORCID if you don't yet have an ORCID iD (instructions on how to do this are included on the account page). For more information, see [here](#). **Please note**, you will only be able to add an ORCID iD to your own account, not your co-authors (the journal editor is also unable to add ORCID iDs on behalf of others). However, we encourage all authors to do so themselves and more information on this will be sent to your co-authors once this manuscript is submitted.

Tapas Sen (Orcid ID: <http://orcid.org/0000-0002-0463-7485>)

- **\*Author for correspondence:** Dr. Indrajit Roy  
(please note only one author can be listed as corresponding author, and should be indicated in the author list with an "\*").
- **Author Contributions:** please list the contributions of each author to the piece; please refer to the [Author Disclosure Form](#) for our authorship criteria.

I certify that each co-author listed on page 1 participated sufficiently in the work to take responsibility for the content, and that all those who qualify are listed.

Name	Affiliation	Contribution
Parul	Delhi University, Delhi, India	conception or design of the work, the acquisition, interpretation of data, drafting the work
Dr. Tapas Sen	UCLAN, Preston, United Kingdom	ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

## Title Page Template

Dr. Indrajit Roy	Delhi University, Delhi, India	Design of the work, revising the draft critically for important intellectual content, final approval of the version to be published
------------------	-----------------------------------	---

- **Acknowledgements:** please refer to the [Author Disclosure Form](#) regarding inclusion of individuals in the author list, versus acknowledging their contributions in this section.

This work is made possible by support from UKIERI-UGC Joint Research Program (UKIERI III) research grant [Contract IND/CONT/G/16-17/62 & F. No. 184-20/2017 (IC)]

- **Financial disclosure:**  
please disclose any financial and/or material support that was received for the research or the creation of the work (please include any grant numbers, funding information etc., here). Also disclose any relationships any authors have (personal, academic or financial relationships that could influence their actions) or financial involvement with an organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. Information not regarding funding should be included in "Acknowledgements".

The authors have no relevant affiliation or financial involvement with any organisations or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript

- **Information pertaining to writing assistance:** **NA**  
has any funded writing assistance been used in the creation of this manuscript? If so, please disclose this and the source of the funding.
- **Ethical disclosure:** please disclose any relevant information regarding the ethical conduct of your research. For studies involving data relating to human or animal experimental investigations, appropriate institutional review board approval is required and should be described within the article and in this disclosure, as per the [ICMJE recommendations on Protection of Research Participants](#), and the further recommendations of the [International Association of Veterinary Editors' Consensus Author Guidelines for Animal Use](#). For those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. In addition, for investigations involving human subjects, authors should obtain informed consent from the participants involved and include an explanation of how this was obtained in the manuscript.
  - **Example wording:** "The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved."
- **Data sharing statement:** for studies reporting the original results of a clinical trial or the secondary analysis of clinical trial data, authors should include a data sharing statement, as described on the ICMJE website: <http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html>. Authors are asked to specify whether their manuscript reports either the original results of a clinical trial, or the secondary analysis of clinical trial data that have been shared with them, and in either case

---

## Title Page Template

include a suitable data sharing statement. Further information, and example wording, can be found in the Author Guidelines on our [website](#).

**Word count:** 4484

**Figure number:** 9

**Table number:** 0